FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
Irene García Megías(Hospital San Pedro), Roberto C. Delgado Bolton(Hospital San Pedro), Kim M. Pabst(West German Heart and Vascular Center Essen), Ken Herrmann(Essen University Hospital), Ludmila Santiago Almeida(Universidade Estadual de Campinas (UNICAMP)), Adriana K. Calapaquí Terán(Marqués de Valdecilla University Hospital), Francesco Giammarile(International Atomic Energy Agency)
Cited by 17
Related Papers
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging
|Neuroendocrinology|2017|495
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Radiotheranostics: a roadmap for future development
|The Lancet Oncology|2020|306
The requirements of a specialist breast centre
|The Breast|2020|195